Javanshir Esfandyari

Laboratorieing
Fler filtreringsmöjligheter
  1. 2021
  2. 2019
  3. Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma

    Sofie Mohlin, Karin Hansson, Katarzyna Radke, Sonia Martinez, Carmen Blanco-Apiricio, Cristian Garcia-Ruiz, Charlotte Welinder, Javanshir Esfandyari, Michael O'Neill, Joaquin Pastor, Kristoffer von Stedingk & Daniel Bexell, 2019 aug 1, I: EMBO Molecular Medicine. 11, 8, e10058.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  4. The Iroquois homeobox proteins IRX3 and IRX5 have distinct roles in Wilms tumour development and human nephrogenesis

    Linda Holmquist Mengelbier, Simon Lindell-Munther, Hiroaki Yasui, Caroline Jansson, Javanshir Esfandyari, Jenny Karlsson, Kimberly Lau, Chi chung Hui, Daniel Bexell, Sevan Hopyan & David Gisselsson, 2019 jan, I: Journal of Pathology. 247, 1

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  5. 2018
  6. Patient-derived xenograft models reveal intratumor heterogeneity and temporal stability in neuroblastoma

    Noémie Braekeveldt, Kristoffer Von Stedingk, Susanne Fransson, Angela Martinez-Monleon, David Lindgren, Håkan Axelson, Fredrik Levander, Jakob Willforss, Karin Hansson, Ingrid Øra, Torbjörn Backman, Anna Börjesson, Siv Beckman, Javanshir Esfandyari, Ana P. Berbegall, Rosa Noguera, Jenny Karlsson, Jan Koster, Tommy Martinsson, David Gisselsson & 2 andra, Sven Påhlman & Daniel Bexell, 2018, I: Cancer Research. 78, 20, s. 5958-5969 12 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift